Background
==========

Polymorphonuclear cell (PMN) activation, adhesion and transpulmonary emigration to the alveolar space are important steps in the pathogenesis of the acute respiratory distress syndrome (ARDS). β~2~ agonists accelerate alveolar fluid clearance and have been suggested as a potential treatment for patients with ARDS. In addition, these agents have a variety of effects on polymorphonuclear cells (PMN). In animal models of sepsis, treatment with β~2~ agonists has been shown to reduce pulmonary neutrophil sequestration and ameliorate the development of lung injury. The aim of this study was to investigate the effect of the β~2~ agonist salbutamol on three aspects of PMN function: PMN activation (CD 64 expression), chemotaxis, and adhesion molecule expression (VLA-4).

Methods
=======

PMNs from 10 healthy volunteers were separated using Ficoll-histopaque gradients and incubated with RPMI or salbutamol (10^-4^ to 10^-10^ M). PMN chemotaxis to FMLP (10^-6^) was determined using the under agarose method. The effects of salbutamol (10^-5^ M and 10^-9^ M) on unstimulated PMN VLA-4 and CD 64 expression were determined using flow cytometry on whole blood.

Results
=======

There was no effect on VLA-4 or CD 64 expression. However, salbutamol did reduce PMN chemotaxis (see Table [1](#T1){ref-type="table"}).

  Salbutamol                      0              10^-9^ M           10^-7^ M    10^-5^ M
  ------------------------------- -------------- ------------------ ----------- ------------------
  Chemotaxis (mm) \[mean (SD)\]   9.3 (1.8)      8.7 (2.3)          8.4 (2.3)   6.7 (1.6)\*
  VLA-4 (MFI) \[median (IQR)\]    10 (1.5--16)   9 (2--20)          X           11 (5.5--25)
  CD 64 (MFI) \[median (IQR)\]    12 (6--18.5)   13.5 (1.7--20.8)   X           10.5 (5.3--26.8)

\* *P* \< 0.05 compared with control. IQR, interquartile range.

Conclusion
==========

Salbutamol reduced PMN chemotaxis but had no effect on VLA-4 adhesion molecule expression or CD 64 expression (PMN activation). β~2~ agonists may have beneficial effects beyond simply enhancing alveolar fluid clearance in patients with ARDS.
